Editor: What To Know
- *Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients.
- “Sarah is a leader with extensive pharmaceutical expertise and I’m delighted to welcome her to our Executive Committee, where she will play a key role in helping us to meet the ambitious organizational efficiency targets set for our industrial operations, required to achieve our transformation,”.
- In 2017 Sarah Dayre was appointed head of operations of the Wuxi site in China, in charge of regional and global markets.
Sarah Dayre will report directly to David Hale, CEO of Guerbet*.
Sarah Dayre is a Doctor of Pharmacy and a graduate of ENSIC in France (Process engineering).
She has gained over 20 years’ experience of pharmaceutical manufacturing and the global supply chain working for AstraZeneca in Europe and Asia.
In 2017 Sarah Dayre was appointed head of operations of the Wuxi site in China, in charge of regional and global markets.
“Sarah is a leader with extensive pharmaceutical expertise and I’m delighted to welcome her to our Executive Committee, where she will play a key role in helping us to meet the ambitious organizational efficiency targets set for our industrial operations, required to achieve our transformation,” said David Hale.
*Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. A pioneer since more than 90 years in the field of contrast media with over 2,800 people globally, Guerbet is continuously innovating with 9% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €817 million in revenue in 2019.
